PATH EX has developed proprietary technology that selectively separates and captures bacteria and toxins from human blood using advanced filtration methods. This process addresses the critical need for effective pathogen removal in medical treatments and blood transfusions, enhancing patient safety and treatment efficacy.
Funding
$3.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Sepsis and other bloodstream infections pose a significant threat, often requiring broad-spectrum antibiotics that contribute to antimicrobial resistance. Current methods for removing pathogens from blood are limited in their ability to selectively target specific bacteria and toxins, potentially leading to incomplete treatment and adverse effects.
Solution
PATH EX has engineered a selective pathogen-capture technology designed to remove bacteria and toxins directly from human blood. The core innovation lies in advanced filtration methods that target specific pathogens, offering a more precise approach compared to broad-spectrum treatments. By selectively removing harmful substances, the technology aims to improve patient outcomes, reduce the reliance on antibiotics, and minimize the risk of antimicrobial resistance. The system is designed for integration into existing medical procedures, enhancing the safety and efficacy of blood transfusions and other treatments.
Target Audience
The primary target audience includes hospitals, blood banks, and medical centers seeking to improve patient safety and treatment outcomes related to bloodstream infections and sepsis.
Features
- Proprietary filtration technology for selective capture of bacteria and toxins
- Targeted pathogen removal to minimize disruption of the blood's natural composition
- Compatibility with standard blood transfusion and extracorporeal circuits
- Scalable design for integration into various clinical settings
- Potential to reduce the need for broad-spectrum antibiotics